Drug Approval | June 22, 2024
Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
The facility will accommodate over 1,500 employees
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Subscribe To Our Newsletter & Stay Updated
